Bengaluru: LB Pharmaceuticals' shares rose 27 per cent in their Nasdaq debut on Thursday, giving the biotech firm a valuation of $381.9 million and opening the door for similarly hopeful companies as the initial public offering fall market heats up. Shares of the New York-based company opened at $19 apiece, compared with its IPO price of $15. It had priced its offering within its marketed range to raise $285 million. Activity in the U.S. IPO market has bumped up going into the fall season as inv

Bengaluru: Intercept Pharmaceuticals said on Thursday it is withdrawing its liver disease drug from the U.S. market following a request from the Food and Drug Administration. This comes as another setback for the company after the U.S. FDA last year declined full approval for the drug, Ocaliva , and said it had identified cases of liver injury in patients who were on it. Ocaliva, chemically known as obeticholic acid , got the FDA's accelerated approval in 2016 to treat patients with primary bili

KalVista Pharmaceuticals’ treatment for a rare disease that causes swelling attacks is enjoying a stronger-than-expected launch, but Wall Street analysts said continued momentum could depend on how often patients return for refills. The biotech’s drug, called Ekterly, reached $1.4 million in US sales as of July 31, according to a Thursday release . Ekterly secured FDA approval in early July for acute attacks of hereditary angioedema (HAE) in adults and children aged 12 years and older. The attac

The global AI in drug discovery industry is projected to reach more than US$ 13.2 Bn by the end of 2035” — By Transparency Market Research WILMINGTON, DE, UNITED STATES, September 12, 2025 / EINPresswire.com / -- The global AI in Drug Discovery Market is witnessing rapid growth, driven by the increasing integration of artificial intelligence technologies in pharmaceutical and biotechnology research. AI platforms are transforming drug discovery by enabling faster identification of novel drug cand

Governments and healthcare systems are advancing adoption of PET scanners, recognizing their vital role in early, accurate, and personalized disease diagnosis. WILMINGTON, DE, UNITED STATES, September 12, 2025 / EINPresswire.com / -- The global positron emission tomography (PET) scanners market has been witnessing steady growth due to rising demand for advanced diagnostic imaging technologies. Valued at US$ 2.2 Bn in 2024, the industry is projected to expand at a CAGR of 3.2% from 2025 to 2035,

Update on Information Relating to the General Meeting of September 30, 2025 61 Founding, Historical, Employee and Executive Shareholders of the Company, Representing Approximately 20.1% of Voting Rights have entered into a Shareholders’ Agreement NANTES, France – September 12, 2025, 8:00 a.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) has been informed of the execution, on September 11, 2025, of a shareholders’ agreement (the “Agreement”) between 61 founding, historical, emp

NANJING, China, Sept. 12, 2025 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced the first patient has been successfully dosed in a Phase 1b/II clinical trial (NCT07099430) evaluating Opamtistomig (LBL-024, PD-L1/4-1BB bispecific antibody) as monotherapy or in combination with other agents for the ‌first-line treatment of advanced melanoma ‌‌. Opamtistomig‌, a uniquely designed PD-L1/4-1BB bispecific antibody that simultaneou

Shares of COVID-19 vaccine developers took a hit Friday after The Washington Post, citing four people familiar with the situation, reported that Trump administration health officials plan to link the preventative shots to the deaths of 25 children in a presentation next week to a vaccine advisory committee for the Centers for Disease Control and Prevention (CDC).Moderna shares declined 7.4%, and Pfizer fell 4%, while US-traded shares of its German partner BioNTech fell 7.3%. Novavax, which marke

An appeals court has rejected Novartis' challenge to the Inflation Reduction Act's (IRA) Medicare drug price negotiation programme, adding to a series of defeats for the pharmaceutical industry on this issue.Novartis sued the US government in 2023, shortly after its heart failure drug Entresto (sacubitril/valsartan) was selected among the first 10 medicines up for negotiation, with the new negotiated prices set to go into effect at the start of 2026. It was one of several companies that have mou

Merck & Co.'s decision this week to walk away from a £1-billion ($1.4 billion) R&D facility in London — and pull its research activities out of the UK altogether — may have triggered a domino effect across big pharma, as Eli Lilly, Sanofi and AstraZeneca now seem to be rethinking their own investments in the country.Following Merck's announcement, John Bell, an immunologist who was a member of the UK government's vaccine task force during the COVID-19 pandemic, appeared on the BBC Radio 4's Toda